Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07277998 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis

Study acronym: RegenOSF
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 11, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Oral Submucous Fibrosis (OSF) is a chronic, progressive, potentially malignant disorder characterized by mucosal stiffness, trismus, and burning sensation. This interventional clinical trial evaluates the therapeutic effectiveness of alternating weekly intralesional Triamcinolone Acetonide (TA) and Platelet-Rich Plasma (PRP) injections compared to standard Triamcinolone therapy alone. The purpose is to determine whether sequential anti-inflammatory (TA) and regenerative (PRP) stimulation can produce superior clinical improvement in mouth opening, burning sensation, and mucosal flexibility compared to corticosteroid therapy alone.
Trial Details
NCT Number NCT07277998
Lead Sponsor Karachi Medical and Dental College
Conditions
(from sponsor)		 Oral Submucous Fibrosis
Related terms Fibrosis, Oral Submucous Fibrosis, Paresthesia, Trismus
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov